Company Filing History:
2 out of 2,168 
1 out of 76 
1 out of 81 
Years Active: 2019-2023
Title: Mihue Jang: Innovator in Cancer Treatment Technologies
Introduction
Mihue Jang is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer treatment through his innovative patents. With a total of 2 patents, Jang's work focuses on advanced therapeutic techniques that aim to improve cancer diagnosis and treatment.
Latest Patents
Jang's latest patents include groundbreaking technologies. The first patent involves immunocytes expressing a chimeric antigen receptor that binds to cancer cells and TNF-related apoptosis-inducing ligand (TRAIL). This invention provides a genetically modified immunocyte that can be used for cancer prevention and treatment. It includes a composition comprising the immunocytes, a cell therapeutic agent, and methods for cancer diagnosis and preparation of the genetically modified immunocyte.
The second patent is for an RNA/DNA nanoparticle designed for siRNA target-specific delivery. This nanoparticle allows for the efficient delivery of siRNA, utilizing a RNA transcript that hybridizes with DNA-cholesterol and folate-DNA conjugates. This technology enhances the stability of siRNA against degradation and allows for selective accumulation in target cancer cells, leading to effective gene-silencing effects within cancer tissues.
Career Highlights
Mihue Jang has worked with notable organizations such as the Korea Institute of Science and Technology and The Asan Foundation. His experience in these institutions has contributed to his expertise in developing innovative cancer treatment technologies.
Collaborations
Jang has collaborated with talented individuals in his field, including Eunsung Jun and Anna Ju. These partnerships have likely fostered a collaborative environment that enhances the development of his innovative ideas.
Conclusion
Mihue Jang is a key figure in the advancement of cancer treatment technologies. His innovative patents reflect his commitment to improving patient outcomes through scientific research and development. His contributions are paving the way for future advancements in cancer therapy.